Clinical trial

Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

NCT01474161

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-11-01

PhasePHASE1

Study timeline

Study start (unknown)2011-11-01Date precision: month

Registry last updated2012-11-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Diabetes Mellitus, Type 2unresolved

Metabolic Diseasesunresolved

Cardiovascular Diseasesunresolved

Obeseunresolved

Dyslipidemiaunresolved

Interventions

GFT505 120mg - old formulationDRUG

GFT505 120mg - new formulationDRUG

GFT505 180mg - new formulationDRUG

GFT505 240mg - new formulationDRUG

GFT505 300mg - new formulationDRUG

Sponsors & collaborators

Genfitlead sponsor

SGS Aster S.A.S.collaborator

Naturalphacollaborator

Mapped research locations

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01474161 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.